From a Pfizer warehouse in Memphis, TN. (Photo courtesy of Pfizer)

Pfiz­er pumps $120M in­vest­ment in­to Kala­ma­zoo plant for Paxlovid pro­duc­tion

As Pfiz­er is con­tin­u­ing to dou­ble down on its Paxlovid ef­forts, more room at its fa­cil­i­ty in Michi­gan will now be re­quired.

The phar­ma will be com­mit­ting $120 mil­lion on its own to its 1,300-acre man­u­fac­tur­ing fa­cil­i­ty in Kala­ma­zoo, MI to en­able US-based pro­duc­tion in sup­port of its Covid-19 oral an­tivi­ral.

Ac­cord­ing to the phar­ma­ceu­ti­cal gi­ant, the in­vest­ment will ex­pand the pro­duc­tion of the API and RSMs used in the man­u­fac­ture of nir­ma­trelvir, a key com­po­nent in Paxlovid. The com­pa­ny ex­pects the ex­pan­sion will cre­ate more than 250 ad­di­tion­al jobs at the Kala­ma­zoo site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.